Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 395


Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.

Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW; ORAR III Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8.


Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.

Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW; ORAR III Investigators.

EuroIntervention. 2009 Jun;5(2):255-64.


Comparison of cost-effectiveness of oral rapamycin plus bare-metal stents versus first generation of drug-eluting stents (from the Randomized Oral Rapamycin in Argentina [ORAR] 3 trial).

Rodriguez AE, Palacios I, Rodriguez-Granillo AM, Mieres JR, Tarragona S, Fernandez-Pereira C, Solorzano L, Pauletto R, Serruys PW, Antoniucci D; ORAR-3 investigators.

Am J Cardiol. 2014 Mar 1;113(5):815-21. doi: 10.1016/j.amjcard.2013.11.033. Epub 2013 Dec 13.


One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).

Mieres J, Fernandez-Pereira C, Risau G, Solorzano L, Pauletto R, Rodriguez-Granillo AM, Rubilar B, Stella P, Rodriguez AE.

Cardiovasc Revasc Med. 2012 Sep-Oct;13(5):265-71. doi: 10.1016/j.carrev.2012.06.001. Epub 2012 Jul 15.


Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.

Tamburino C, Barbagallo R, Capodanno D, di Matteo S, Colombo GL, Recchia M, Ciriminna S; Sicilian DES Registry Investigators.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):322-9. doi: 10.2459/JCM.0b013e3283276ebb.


The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.

Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW; Interventional Cardiologists of the Thoraxcenter.

JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.


A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.


Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation.

Varani E, Guastaroba P, Di Tanna GL, Saia F, Balducelli M, Campo G, Vignali L, Rossi R, Manari A, Piovaccari G, De Palma R, Marzocchi A.

EuroIntervention. 2010 Apr;5(8):953-61. doi: 10.4244/.


Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.


Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.

Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.

Arch Cardiovasc Dis. 2013 Nov;106(11):554-61. doi: 10.1016/j.acvd.2013.06.056. Epub 2013 Nov 11.


Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.

Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P; RESOLUTE All Comers; RESOLUTE International Investigators.

JACC Cardiovasc Interv. 2013 Sep;6(9):905-13. doi: 10.1016/j.jcin.2013.04.017. Epub 2013 Aug 14.


Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial.

Canoui-Poitrine F, Jeanblanc G, Alberti C, Armoogum P, Cebrian A, CarriƩ D, Henry P, Teiger E, Slama M, Spaulding C, Durand-Zaleski I.

Appl Health Econ Health Policy. 2009;7(1):19-29. doi: 10.2165/00148365-200907010-00003.


Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.

Yu X, Chen F, He J, Gao Y, Wu C, Luo Y, Zhang X, Zhang Y, Ren X, Lv S.

Coron Artery Dis. 2013 May;24(3):217-23. doi: 10.1097/MCA.0b013e32835c8f74.


Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.

Zbinden R, von Felten S, Wein B, Tueller D, Kurz DJ, Reho I, Galatius S, Alber H, Conen D, Pfisterer M, Kaiser C, Eberli FR.

Cardiovasc Ther. 2017 Feb;35(1):19-25. doi: 10.1111/1755-5922.12229.


Bare-metal stent versus drug-eluting stent in large coronary arteries: meta-analysis of randomized controlled trials.

Geng DF, Meng Z, Yan HY, Nie RQ, Deng J, Wang JF.

Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1087-94. doi: 10.1002/ccd.24599. Epub 2013 Feb 26.


Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.

Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.

Catheter Cardiovasc Interv. 2013 May;81(6):E237-44. doi: 10.1002/ccd.24513. Epub 2012 Nov 14.


Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.

Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2008 Apr 1;71(5):594-8. doi: 10.1002/ccd.21399.


Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.

Almalla M, Pross V, Marx N, Hoffmann R.

Coron Artery Dis. 2012 Nov;23(7):492-6.


Supplemental Content

Support Center